Influence of Care Pathway on Thyroid Nodule Surgery Relevance: A Historical Cohort Study.

care pathway fine-needle aspiration cytology guidelines thyroid cancer thyroid nodule

Journal

Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588

Informations de publication

Date de publication:
17 Jul 2020
Historique:
received: 19 06 2020
accepted: 15 07 2020
entrez: 26 7 2020
pubmed: 28 7 2020
medline: 28 7 2020
Statut: epublish

Résumé

Guidelines recommend using fine-needle aspiration cytology (FNAC) to guide thyroid nodule surgical indication. However, the extent to which these guidelines are followed remains unclear. This study aimed to analyze the quality of the preoperative care pathway and to evaluate whether compliance with the recommended care pathway influenced the relevance of surgical indications. Nationwide historical cohort study based on data from a sample (1/97th) of French health insurance beneficiaries. Evaluation of the care pathway of adult patients operated on between 2012 and 2015 during the year preceding thyroid nodule surgery. The pathway containing only FNAC was called "FNAC", the pathway including an endocrinology consultation (ENDO) with FNAC was called "FNAC+ENDO", whereas the no FNAC pathway was called "NO FNAC". The main outcome was the malignant nature of the nodule. Among the 1080 patients included in the study, "FNAC+ENDO" was found in 197 (18.2%), "FNAC" in 207 (19.2%), and "NO FNAC" in 676 (62.6%) patients. Cancer diagnosis was recorded in 72 (36.5%) "FNAC+ENDO" patients and 66 (31.9%) "FNAC" patients, against 119 (17.6%) "NO FNAC" patients. As compared to "NO FNAC", the "FNAC+ENDO" care pathway was associated with thyroid cancer diagnosis (OR 2.67, 1.88-3.81), as was "FNAC" (OR 2.09, 1.46-2.98). Surgeries performed in university hospitals were also associated with thyroid cancer diagnosis (OR 1.61, 1.19-2.17). Increasing the year for surgery was associated with optimal care pathway (2015 vs. 2012, OR 1.52, 1.06-2.18). The recommended care pathway was associated with more relevant surgical indications. While clinical guidelines were insufficiently followed, compliance improved over the years.

Sections du résumé

BACKGROUND BACKGROUND
Guidelines recommend using fine-needle aspiration cytology (FNAC) to guide thyroid nodule surgical indication. However, the extent to which these guidelines are followed remains unclear. This study aimed to analyze the quality of the preoperative care pathway and to evaluate whether compliance with the recommended care pathway influenced the relevance of surgical indications.
METHODS METHODS
Nationwide historical cohort study based on data from a sample (1/97th) of French health insurance beneficiaries. Evaluation of the care pathway of adult patients operated on between 2012 and 2015 during the year preceding thyroid nodule surgery. The pathway containing only FNAC was called "FNAC", the pathway including an endocrinology consultation (ENDO) with FNAC was called "FNAC+ENDO", whereas the no FNAC pathway was called "NO FNAC". The main outcome was the malignant nature of the nodule.
RESULTS RESULTS
Among the 1080 patients included in the study, "FNAC+ENDO" was found in 197 (18.2%), "FNAC" in 207 (19.2%), and "NO FNAC" in 676 (62.6%) patients. Cancer diagnosis was recorded in 72 (36.5%) "FNAC+ENDO" patients and 66 (31.9%) "FNAC" patients, against 119 (17.6%) "NO FNAC" patients. As compared to "NO FNAC", the "FNAC+ENDO" care pathway was associated with thyroid cancer diagnosis (OR 2.67, 1.88-3.81), as was "FNAC" (OR 2.09, 1.46-2.98). Surgeries performed in university hospitals were also associated with thyroid cancer diagnosis (OR 1.61, 1.19-2.17). Increasing the year for surgery was associated with optimal care pathway (2015 vs. 2012, OR 1.52, 1.06-2.18).
CONCLUSIONS CONCLUSIONS
The recommended care pathway was associated with more relevant surgical indications. While clinical guidelines were insufficiently followed, compliance improved over the years.

Identifiants

pubmed: 32708905
pii: jcm9072271
doi: 10.3390/jcm9072271
pmc: PMC7408692
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

Clin Endocrinol (Oxf). 2007 Jun;66(6):844-53
pubmed: 17437521
BMJ. 2013 Aug 27;347:f4706
pubmed: 23982465
Ann Endocrinol (Paris). 2001 Dec;62(6):499-506
pubmed: 11845024
N Engl J Med. 2014 Nov 6;371(19):1765-7
pubmed: 25372084
Am J Clin Pathol. 2010 Sep;134(3):450-6
pubmed: 20716802
Clin Endocrinol (Oxf). 2018 Dec;89(6):824-833
pubmed: 30103256
Cytopathology. 2019 Sep;30(5):468-474
pubmed: 31206845
N Engl J Med. 2015 Dec 10;373(24):2347-56
pubmed: 26650154
N Engl J Med. 2015 Dec 10;373(24):2389-90
pubmed: 26650173
Surgery. 2014 Aug;156(2):399-404
pubmed: 24947642
Cancer Epidemiol. 2015 Aug;39(4):511-8
pubmed: 26003877
Thyroid. 2013 Apr;23(4):449-55
pubmed: 23067375
J Clin Endocrinol Metab. 2019 Jan 1;104(1):95-102
pubmed: 30299457
Thyroid. 2016 Nov;26(11):1541-1552
pubmed: 27571228
Surgery. 2017 Jan;161(1):156-165
pubmed: 27866716
N Engl J Med. 2016 Aug 18;375(7):614-7
pubmed: 27532827
Exp Clin Endocrinol Diabetes. 2017 May;125(5):327-334
pubmed: 28255971
Ann Endocrinol (Paris). 2011 Sep;72(4):251-281
pubmed: 21782154
Dtsch Arztebl Int. 2013 Dec 6;110(49):827-34
pubmed: 24355935
PLoS One. 2017 Jun 14;12(6):e0179387
pubmed: 28614405
Thyroid. 2018 Jan;28(1):23-31
pubmed: 28629253
Surgery. 2016 Jan;159(1):41-50
pubmed: 26435426
J Cytol. 2014 Apr;31(2):73-8
pubmed: 25210233
Transl Res. 2017 Oct;188:58-66.e1
pubmed: 28797549
Thyroid. 2015 Oct;25(10):1127-36
pubmed: 26133012
J Clin Endocrinol Metab. 2016 Jul;101(7):2853-62
pubmed: 27014951
BMJ Open. 2017 Apr 7;7(4):e013589
pubmed: 28389487
Surgery. 2019 Oct;166(4):691-697
pubmed: 31402128
Lancet Oncol. 2014 May;15(6):e234-42
pubmed: 24807866
Thyroid. 2012 Feb;22(2):117-24
pubmed: 22191388
Thyroid. 2009 Nov;19(11):1167-214
pubmed: 19860577
Ann Oncol. 2019 Dec 1;30(12):1856-1883
pubmed: 31549998
Clin Endocrinol (Oxf). 2014 Jul;81 Suppl 1:1-122
pubmed: 24989897
Am J Surg. 2010 Feb;199(2):189-98
pubmed: 20113699
Thyroid. 2017 Nov;27(11):1341-1346
pubmed: 29091573
Eur Thyroid J. 2017 Sep;6(5):225-237
pubmed: 29167761
Endocrinol Diabetes Metab. 2018 Jun 19;1(3):e00024
pubmed: 30815558
Acta Cytol. 2012;56(4):333-9
pubmed: 22846422
Eur J Clin Invest. 2009 Aug;39(8):699-706
pubmed: 19601965
J Clin Endocrinol Metab. 2018 Jun 1;103(6):2362-2368
pubmed: 29672763
Ann Endocrinol (Paris). 2015 Feb;76(1 Suppl 1):1S16-26
pubmed: 26826478
JAMA. 2018 Mar 6;319(9):914-924
pubmed: 29509871
Thyroid. 2016 Jan;26(1):1-133
pubmed: 26462967
Eur Thyroid J. 2014 Sep;3(3):154-63
pubmed: 25538897
World J Surg. 2010 Jan;34(1):28-35
pubmed: 20020290
Int J Surg. 2018 Jun;54(Pt A):100-104
pubmed: 29709542
Lancet Diabetes Endocrinol. 2016 Nov;4(11):933-942
pubmed: 27550849
Thyroid. 2020 May 14;:
pubmed: 32292128
BMJ. 2012 Jan 10;344:d8041
pubmed: 22236412

Auteurs

Solène Castellnou (S)

Endocrinology Department, Groupement Hospitalier Est, Hospices Civils de Lyon, 69500 Bron, France.

Jean-Christophe Lifante (JC)

Endocrine Surgery Department, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, 69310 Pierre Bénite, France.
Health Services and Performance Research Lab (EA 7425 HESPER), Université Claude Bernard Lyon 1, 69100 Villeurbanne, France.

Stéphanie Polazzi (S)

Health Services and Performance Research Lab (EA 7425 HESPER), Université Claude Bernard Lyon 1, 69100 Villeurbanne, France.
Health Data Department, Hospices Civils de Lyon, 69003 Lyon, France.

Léa Pascal (L)

Health Data Department, Hospices Civils de Lyon, 69003 Lyon, France.

Françoise Borson-Chazot (F)

Endocrinology Department, Groupement Hospitalier Est, Hospices Civils de Lyon, 69500 Bron, France.
Health Services and Performance Research Lab (EA 7425 HESPER), Université Claude Bernard Lyon 1, 69100 Villeurbanne, France.

Antoine Duclos (A)

Health Services and Performance Research Lab (EA 7425 HESPER), Université Claude Bernard Lyon 1, 69100 Villeurbanne, France.
Health Data Department, Hospices Civils de Lyon, 69003 Lyon, France.

Classifications MeSH